Some noteworthy PSGs include dihydroergotamine mesylate nasal spray, glucagon nasal powder, afamelanotide subcutaneous implant, and triamcinolone acetonide injectable suspension.
On Feb. 16 2023, FDA published a new set of product-specific guidance documents that provide recommendations for developing generic drugs and creates evidence to support abbreviated new drug application (ANDA) approvals, which helps to streamline generic product and ANDA assessment.
The FDA publishes PSGs to help facilitate generic drug competition, supporting greater access to safe, effective, and potentially lower-cost treatments. Additionally, improving access to high-quality, affordable medicines helps the agency’s mission to advance public health.
The recent group of 30 PSGs includes:
Some noteworthy PSGs include dihydroergotamine mesylate nasal spray, glucagon nasal powder, afamelanotide subcutaneous implant, and triamcinolone acetonide injectable suspension.
The FDA also updated their “Upcoming Product-Specific Guidances for Generic Drug Product Development” website to include PSG revision categories and brief descriptions of the revisions that will help applicants in determining if a PSG revision may impact their generic drug development program.
Source: FDA
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.